Egypt's cancer therapeutics market has experienced steady growth, driven by increasing cancer prevalence, an aging population, and rising public awareness about health. Cancer remains a major cause of mortality in the country, with the number of newly diagnosed cases continuing to climb. According to GLOBOCAN 2020 data, Egypt recorded approximately 134,632 new cancer cases and 89,042 deaths related to cancer that year. This growing health challenge has fueled demand for advanced treatment options such as chemotherapy, targeted therapies, and immunotherapy.
Efforts to tackle the cancer burden have gained momentum through both government-led initiatives and international partnerships. The Egyptian Ministry of Health and Population (MOHP) has made cancer care a key focus by enhancing services across both public and private healthcare sectors. Notably, the National Cancer Institute (NCI) in Cairo—one of the country's premier cancer treatment and research institutions—offers a wide range of services, from early detection to specialized treatment. The institute is also actively involved in researching cancer trends and patterns specific to Egypt, helping shape more effective responses to the disease.
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Egypt Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Egypt Cancer Therapeutics Market – Analysis
- 6.1 Egypt Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Egypt Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Egypt Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Egypt Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Egypt Cancer Therapeutics Market Analysis – by Indications
- 8.1 Egypt Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Egypt Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Egypt Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Egypt Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Egypt Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Egypt Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Egypt Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Egypt Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Egypt Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Egypt Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Egypt Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Egypt Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Egypt Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook